US 12,336,985 B2
Methods for shrinking pituitary tumors
Andreas Moraitis, Sunny Isles Beach, FL (US)
Assigned to Corcept Therapeutics Incorporated, Redwood City, CA (US)
Filed by Corcept Therapeutics Incorporated, Menlo Park, CA (US)
Filed on May 2, 2024, as Appl. No. 18/653,070.
Application 18/653,070 is a continuation of application No. 17/185,133, filed on Feb. 25, 2021, granted, now 12,005,055.
Application 17/185,133 is a continuation of application No. 16/678,988, filed on Nov. 8, 2019, granted, now 10,946,005, issued on Mar. 16, 2021.
Claims priority of provisional application 62/758,477, filed on Nov. 9, 2018.
Prior Publication US 2024/0277686 A1, Aug. 22, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/444 (2006.01); A61B 17/3205 (2006.01); A61N 5/10 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/444 (2013.01) [A61P 35/00 (2018.01); A61B 17/3205 (2013.01); A61N 5/10 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A method of reducing the size of a visible pituitary macroadenoma tumor in a patient suffering from said tumor, the tumor not having been treated with radiation, the method comprising imaging said visible pituitary macroadenoma tumor effective to determine a first size of said tumor, and then administering for three months to the patient daily oral doses of between about 100 milligrams (mg) and about 200 mg of relacorilant, where relacorilant is ((R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone), which has the following structure:

OG Complex Work Unit Chemistry
effective to reduce the size of the visible pituitary macroadenoma tumor from said first size of the visible pituitary macroadenoma tumor to a second size of the visible pituitary macroadenoma tumor, wherein said second size of the visible pituitary macroadenoma tumor is smaller than the first size of the visible pituitary macroadenoma tumor.